Valeant Readies For More Expansion In 2011
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma is gearing up for as many as four more "tuck-in" acquisitions after completing a reverse-merger with Biovail and acquiring PharmaSwiss.
You may also be interested in...
Valeant Continues Buying Spree With $2.6B Acquisition Of Medicis
The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.
Valeant Discusses Strategy, Reflects On Four Years Of Growth
True to form, the contrarian CEO of Valeant tells analysts that his company favors investment in business development over share buybacks, out-of-the spotlight emerging markets (Southeast Asia, South Africa, and Eastern and Central Europe), and niche therapeutic areas like dermatology and ophthalmology, all largely cash markets, where Valeant can stress its brand and distribution capabilities over scientific innovation.
Valeant Adds Eyetech’s Macugen To Ophthalmic Portfolio
The acquisitive Canadian specialty pharma’s latest deal is a relatively small one, giving it a wet AMD treatment that lags behind Lucentis and other newcomers.